Eli Lilly Files 8-K Detailing Debt Offerings

TL;DR

LLY just dropped an 8-K detailing a bunch of new debt notes with varying maturity dates and interest rates.

AI Summary

Eli Lilly and Company (LLY) filed an 8-K on February 12, 2025, reporting other events and financial statements. The filing details various debt issuances, including notes due in 2025, 2026, 2030, 2031, 2033, 2036, 2043, 2049, 2051, and 2061, with interest rates ranging from 1.625% to 6.77%.

Why It Matters

This filing indicates Eli Lilly is actively managing its capital structure through significant debt issuances, which could impact its financial leverage and future investment capacity.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of debt issuances and does not indicate any immediate operational or financial distress.

Key Numbers

• 1.625% — Lowest Interest Rate (On notes due 2026 and 2049)
• 6.77% — Highest Interest Rate (On notes due 2036)
• 2061 — Latest Maturity Date (For a debt issuance)

Key Players & Entities

• Eli Lilly & Co (company) — Filer
• LLY (company) — Ticker Symbol
• 0000059478 (company) — Central Index Key
• 20250212 (date) — Filing Date
• 20250210 (date) — Period of Report

FAQ

Key Financial Figures

• $1,000,000,000 — the issuance and sale by the Company of $1,000,000,000 aggregate principal amount of its 4.550
• $1,250,000,000 — 550% Notes due 2028 (the "2028 Notes"), $1,250,000,000 aggregate principal amount of its 4.750
• $750,000,000 — % Notes due 2055 (the "2055 Notes") and $750,000,000 aggregate principal amount of its 5.600
• $6.46 billion — Company, net proceeds of approximately $6.46 billion. Upon the occurrence of an Event of D

Filing Documents

• d868986d8k.htm (8-K) — 50KB
• d868986dex11.htm (EX-1.1) — 260KB
• d868986dex43.htm (EX-4.3) — 222KB
• d868986dex51.htm (EX-5.1) — 15KB
• d868986dex52.htm (EX-5.2) — 11KB
• g868986dsp138.jpg (GRAPHIC) — 4KB
• g868986dsp139.jpg (GRAPHIC) — 2KB
• g868986g0211121418746.jpg (GRAPHIC) — 3KB
• g868986g0211221026253.jpg (GRAPHIC) — 2KB
• 0001193125-25-025057.txt ( ) — 900KB
• lly-20250210.xsd (EX-101.SCH) — 6KB
• lly-20250210_def.xml (EX-101.DEF) — 16KB
• lly-20250210_lab.xml (EX-101.LAB) — 28KB
• lly-20250210_pre.xml (EX-101.PRE) — 18KB
• d868986d8k_htm.xml (XML) — 16KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 1.1 Underwriting Agreement, dated February 10, 2025, among Eli Lilly and Company and Barclays Capital Inc., BofA Securities, Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc. and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein. 4.1* Indenture, dated February 1, 1991, among Eli Lilly and Company and Deutsche Bank Trust Company Americas, as successor to Citibank, N.A., as Trustee. 4.2 Tripartite Agreement, dated September 13, 2007, appointing Deutsche Bank Trust Company Americas as Successor Trustee under the Indenture listed above. 4.3 Form of Officers' Certificate setting forth the terms and form of the Notes. 4.4 Form of 4.550% Note due 2028 (included in Exhibit 4.3 above). 4.5 Form of 4.750% Note due 2030 (included in Exhibit 4.3 above). 4.6 Form of 4.900% Note due 2032 (included in Exhibit 4.3 above). 4.7 Form of 5.100% Note due 2035 (included in Exhibit 4.3 above). 4.8 Form of 5.500% Note due 2055 (included in Exhibit 4.3 above). 4.9 Form of 5.600% Note due 2065 (included in Exhibit 4.3 above). 5.1 Opinion of Kirkland & Ellis LLP. 5.2 Opinion of Jonathan Groff, Esq. 23.1 Consent of Kirkland & Ellis LLP (included as part of Exhibit 5.1). 23.2 Consent of Jonathan Groff, Esq. (included as part of Exhibit 5.2). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Incorporated by reference to the same-numbered exhibit of the Company's Registration Statement on Form S-3 (File No. 333-186979), filed with the Securities and Exchange Commission ("SEC") on March 1, 2013. Incorporated by reference to the same-numbered exhibit of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 (File No. 001-06351), filed with the SEC on February 27, 2009.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ELI LILLY AND COMPANY (Registrant) By: /s/ Jon Haug Name: Jon Haug Title: Senior Vice President, Treasurer and Corporate Finance and Investment Banking Dated: February 12, 2025

View Full Filing

View this 8-K filing on SEC EDGAR